Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis - A case series

Clinical Rheumatology

Volumn 33, Issue 6, 2014, Pages 841-848

  Knight, A ^a   Hallenberg, H ^a   Baecklund, E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Granulomatosis with polyangiitis; Infections; Maintenance therapy; Rituximab; Safety

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; BONE NECROSIS; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FOLLOW UP; GRANULOMATOSIS WITH POLYANGIITIS; HUMAN; INFECTION; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURIGO; RELAPSE; RETROSPECTIVE STUDY; SYSTEMIC VASCULITIS; YOUNG ADULT; IMMUNOLOGY; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903821131     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2351-y     Document Type: Article

References (29)

1. Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488-498
2. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W et al (2009) for the European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310-317
3. Knight A, Askling J, Granath F, Sparen P, Ekbom A (2004) Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63:1307-1311 (Pubitemid 39273514)
4. Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36-44 (Pubitemid 36765101)
5. Pagnoux C, Hogan SL, Chin H et al (2008) Predictors of treatment resistance and relapse in anti neutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 58:2908-2918
6. Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 20:517-527 (Pubitemid 38638122)
7. Popa ER, Stegeman CA, Bos NA, Kallenberg CA, Tervaert JW (1999) Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 103:885-894 (Pubitemid 29297593)
8. Cupps TR, Edgar LC, Fauci AS (1982) Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 128:2453-2457 (Pubitemid 12124460)
9. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232, for the RAVEITN Research Group
10. Jones RB, Tervaert JWC, Hauser T, Luqmani R et al (2010) Rituximab versus cyclophosphamide in ANCA associated renal vasculitis. N Engl J Med 363:211-220
11. Holle J, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculiticmanifestations. Ann Rheum Dis 71:327-333
12. Jones RB, Ferraro AJ, Chaudhry AN et al (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 7:2156-2168
13. Wendt M, Gunnarson I, Bratt J, Bruchfeld A (2012) Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol 41:116-119
14. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540-548
15. Rhee EP, Laliberte KA, Niles JL (2010) Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5:1394-1400
16. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J et al (2012) Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39:125-130, for the French Vasculitis Study Group
17. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez- Menéndez M, Ytterberg SR et al (2012) Rituximab for remission induction and maintenance treatment in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64:3770-3778
18. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A et al (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3760-3769
19. Specks U (2012) Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med 79(Suppl 3):50-53
20. Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X (2012) B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev 11:646-652
21. Emery P, Mease PJ, Rubbert-Roth A et al (2011) Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) 50:2223-2232
22. Leavitt RY, Fauci A, Block D, Michel B, Hunder G, Arend W et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101-1107 (Pubitemid 20273294)
23. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192 (Pubitemid 24065492)
24. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB et al (2001) A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:912-920 (Pubitemid 32319784)
25. Hellmich B, Flossman O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605-617 (Pubitemid 46707128)
26. Lyons PA, Rayner TF, Sapna Trivera MR et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214-233
27. Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, Palmblad J (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63:2209-2214
28. Carson KR, Evens AM, Richey EA et al (2009) Progressive multi-focal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834-4840
29. Vollenhoven RF, Emery P, Bingham CO et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558-567